r/Canadapennystocks

Posted on behalf of Star Copper Corp. - Copper’s long-term demand curve continues to steepen—and China remains the anchor.

New forecasts from China Minmetals point to ~3.7% annual copper demand growth through 2035, driving consumption from ~16Mt to ~22.9Mt (+43%), with upside to 50%+ growth if intensity levels hold.

Near-term growth may moderate (~1% in 2026), but the structural trend remains intact:

• Electrification, grid buildout, and infrastructure continue to underpin demand

• Per capita copper usage in China still trails developed markets

• Even with population decline, absolute demand continues to rise

At the same time:

• Supply remains constrained (grade decline, permitting delays)

• Development timelines (~15–20 years) limit near-term supply response

• Long-term price assumptions across the industry continue to move higher

Implication: The copper market is increasingly defined by a structural deficit, not cyclical swings.

Against this backdrop, Star Copper Corp. is entering a critical phase in 2026 with a fully funded 15,000m drill program aimed at transitioning from exploration to resource definition.

Program highlights:

• Multi-target drilling across Star Main, Copper Creek, Star North, East, and West

• Fully funded with $12M+, removing near-term dilution risk

• Prior results at Copper Creek: 57m @ 0.61% CuEq (within 111m @ 0.35% CuEq)

• Large-scale untested anomalies (e.g., 1km x 1km at Star East)

Execution edge:

• Integrated 3D geological modelling + IP/MT geophysics

• Targeting deeper sulphide systems and higher-grade cores

• Designed to test both scale and continuity of a porphyry system

As long-term copper demand resets higher, projects with scale potential in Tier-1 jurisdictions become increasingly strategic. Star Copper’s 2026 program is positioned to test exactly that—scale, depth, and resource potential—at a time when the market is actively repricing future copper supply.

https://www.kitco.com/news/off-the-wire/2026-04-15/china-copper-consumption-grow-37-annually-through-2035-minmetals-says

• New Found Gold has announced a comprehensive C$205M finance package comprising a C$100M bought deal equity financing and a C$105M senior secured credit facility, both anchored by EdgePoint Investment Group, with cornerstone investor Eric Sprott participating in the equity component.
• The package replaces a previously announced US$75M debt term sheet with Nebari Natural Resources Credit Fund II and is structured to fully fund the C$155M capital cost outlined in the Queensway PEA, with an overrun buffer built into the facility.
• EdgePoint, entering as both the lead lender and co-lead underwriter on the equity, is making its first meaningful position in New Found Gold at market price, signalling institutional conviction in the Queensway asset's near-term production economics.
• CEO Keith Boyle confirmed there has been no change to timing or strategy, with first production from Queensway still targeted for end of 2027, and construction expected to begin this summer following permit amendments and environmental assessment submission.
• With Hammerdown approaching commercial production in the second half of 2025 and Queensway projecting approximately 100,000 ounces per year at an all-in sustaining cost of around $1,300 per ounce in its first years of operation, management sees the company as positioned for a significant re-rate as it transitions from developer to producer.

Sponsored publication on behalf of the issuer
TORONTO, ON / ACCESS Newswire / April 17, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share in consideration of past services and satisfaction of outstanding indebtedness.

The Subject Shares are subject to a statutory hold period expiring on August 18, 2026.

Insiders of the Company have purchased, directly or indirectly, an aggregate of 11,848,000 Subject Shares, as a result of which the issuance is a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61- 101"). The Company is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to the exemptions contained in Sections 5.5(b) and 5.7(1)(a) of MI 61-101 on the basis that the Company is listed on the Canadian Securities Exchange and neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the Subject Shares, insofar as it involves the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101).

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About AI/ML Innovations Inc.

AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care. AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

Fellow resource chads, miners, and anyone tired of chasing Chinese supply chains,

Antimony prices are on absolute fire right now. Today (Apr 12) it hit $46,075 per tonne – the highest in the past 30 days. That's a clean ~38% rip higher from the March 13 low around $33k, with a steady, low-pullback grind the entire way up. Just look at the 30-day chart: beautiful upward channel, minimal dips, and a nice breakout feel as we head into spring.

What's driving the surge? Simple supply/demand imbalance on steroids:

• China (which controls ~85% of global processing) has slammed on export restrictions, especially on dual-use materials.
• Exploding demand from solar/tech (sodium antimonide in PV panels), flame retardants, semiconductors, and massive military applications (ammunition hardening, night vision, etc.).

Western governments are now in full scramble mode for secure, non-Chinese antimony supply. This is a critical mineral moment.

And right in the middle of it sits Military Metals Corp (MILI) – the only meaningful antimony developer in all of Europe.

Their flagship Trojárova (Trojarova) project in Slovakia just dropped a maiden Inferred Resource (announced April 8) that screams "multi-bagger potential":

• 6.5 million tonnes at 1.02% Sb + 1.06 g/t Au
• Containing 67,000 tonnes of contained antimony and 222,000 ounces of gold
• Largest modern (NI 43-101) antimony resource in the entire EU

Why this is ridiculously bullish (Scott's own words in the update):

• Massive historical dataset: 63 drill holes already done before they even showed up. They only needed 7 additional holes to validate and publish the resource. That alone tells you how continuous and high-confidence the mineralization is.
• The system is wide open along strike and at depth — every indication points to significant growth in both size and grade.
• Gold by-product is a game-changer. Based on current data, the gold credits could offset the majority (if not all) of operating costs once in production. This turns Trojarova into a potential low-cost, high-margin beast.
• Existing underground infrastructure (1.7 km adit + drives from the 1990s) makes it "plug-and-play" with minimal capex and a super-short timeline to production.
• 100% owned and now royalty-free.

Valuation? It's actually embarrassing how cheap this is compared to peers:

Company	Jurisdiction	Tonnes Sb	Grade (Sb)	Market Cap	$/tonne Sb
Military Metals	Europe	67,000	1.02%	$40M	$597
Larvotto Resources	Australia	96,000	1.10%	$627M	$6,531
Perpetua Resources	USA	67,000	0.06%	$5B	$74,627

Military Metals is trading at a fraction of what the Aussie and US peers are getting for similar (or worse) assets. Europe gets the strategic premium + CRMA funding tailwinds, and they have the best infrastructure and by-product credits.

This isn't hype — it's the perfect storm: antimony at all-time recent highs, Europe desperate for domestic supply, a de-risked resource with gold paying the bills, and a market cap that still looks like a junior explorer from 2023.

Position accordingly, friends. MILI is the only pure-play European antimony ticket in the entire sector, and the wind is at its back like never before.

This could easily be a 5-10x as prices keep climbing and they derisk further toward production.

DYOR, NFA, but damn… this one feels special. LFG.

Looked into DAN since their april update and this one actually feels bigger than it looked at first. They reported new test work showing about 80% of their phosphoric acid can be upgraded into PPA (the high quality “white acid”) vs older estimates closer to like 65%, doesn’t sound insane but that shift actually matters a lot as phosphate ends up as different products and PPA is the premium one used in stuff like EV batteries (LFP) and food additives. The more of that you can produce vs lower grade fertilizer acid the better your margins get so going from 65% → 80% is kind of a big deal because it means more high margin product from the same rock. You’re not mining more, just selling better stuff.

PPA is also a mandatory input for EV batteries. China currently controls over 95% of LFP production and arianne is positioning itself as the most viable, large-scale Western alternative. Phosphate was recently added to the Critical Minerals lists of Canada and the United States (late 2025). Being located in a stable jurisdiction like Quebec removes the "sovereign risk" associated with other major producers (like Morocco or China) and makes the project eligible for government support and strategic partnerships. Arianne owns the only fully permitted greenfield phosphate mine in the West which makes them really unique.

Been thinking about this more lately... location.

A few years ago, it felt like all that mattered was the deposit. Big resource, good grades, upside potential. That was the whole story.

But with everything going on now, including the Iran–U.S. tension and the noise around key shipping routes like the Strait of Hormuz, it feels like people are starting to look at things a bit differently. Not just what’s in the ground, but also where it is.

A good deposit is still a good deposit, obviously. But now there’s that extra layer stability, permitting, infrastructure, and how realistic it is to actually move a project forward.

Places like South America still produce some incredible discoveries. Names like NGEx ($NGEX) and ATEX ($ATEX) are proof of that. The geology there is hard to ignore.

At the same time, I keep noticing more attention going toward U.S. and Canada-based projects. That’s part of what put $CQX on my radar. Their Auxer gold project in Idaho already has some groundwork behind it historic underground workings, road access, and permits in place for upcoming drilling. To me, that makes it feel a bit more tangible than the usual early-stage story.

And it’s not just one asset. They’ve also got the Kitimat copper project in British Columbia, plus a few other exploration projects, so there’s at least some broader exposure there.

Still, it’s early-stage, and a lot has to go right from here. Drilling, funding, execution—it all matters.

I’m not saying location matters more than the deposit. But it does feel like geopolitics is making people pay more attention to jurisdiction than they used to.

Am I overreading that, or are others seeing the same shift?

Disclosure: this post is sponsored. Not financial advice. Always do your own DD.

I’ve been trying to piece together the bigger picture on $SKUR, and what keeps coming up is how the milestones are starting to line up into a broader strategy.

Here’s how the path looks so far:

• Built outside Big Tech from day one
Everything runs on Swiss-hosted infrastructure with no reliance on Amazon, Google, or Microsoft. That creates a very different setup around privacy and data sovereignty.

• Opened a direct path into U.S. government procurement
Sekur’s solutions were listed under a GSA Multiple Award Schedule contract, giving federal, state, and local agencies a pre-competed path to procure its secure communications tools.

• Started expanding internationally
The company signed its first distribution agreement in the Democratic Republic of Congo through Mokilink Services, with sales expected by the end of Q2 2026.

• Moving upmarket with Sekur Platinum
Sekur Platinum is scheduled to launch in May 2026 and will add encrypted anonymous voice and video calling with no phone number required. Pricing is around US$7,000 per user annually.

• Defined a financial target
Sekur is operating with high SaaS margins (around 80%) and is targeting cash-flow neutrality by Q1 2027.

Put together, it reads less like a bunch of separate updates and more like the company slowly building things out step by step. First the infrastructure, then government access, then international expansion, then the higher-end product push, and now the financial target.

https://preview.redd.it/oa8sya8b7kvg1.jpg?width=1600&format=pjpg&auto=webp&s=70e50d971e2b071e2a701283c085e9988bb7825d

Sponsored post. DYOR.

been following natural hydrogen for a while and honestly most of the conversation in this space has been about exploration. finding the gas. but anyone who has been paying attention knows that was never really the hard part.

the real bottleneck is getting it out at rates that make commercial sense. serpentinization happens on geological timescales. great for the planet, useless for a balance sheet.

element one put out an update april 14 on a patent pending tech that seems to be going after this directly. instead of bringing in external feedstocks they are using minerals already in the rock to create catalysts in situ. lab results showed over 1000x increase in hydrogen generation versus standard iron benchmarks.

now here is where it gets interesting to debate.

academic consensus for commercial viability sits around 10000x above natural background rates. so element one is showing 1000x in a lab against a different baseline. is that a genuine breakthrough in the right direction or is it just a well framed press release.

the two pathway approach is smart though. subsurface injection is the big prize but heavy capital. above ground reactors using mined rock could prove the concept faster and at lower cost. if that works the cost structure looks genuinely different from anyone having to manufacture and transport reagents.

field testing is the next thing to watch and that is where most of these stories either get real or fall apart.

so genuinely curious. does the lab number move the needle for anyone here or are we still too far from commercial reality to get excited about this

not financial advice just find the technical side of this space genuinely interesting

What is your suggested approach to names in the AI-driven healthcare / diagnostics space at this stage?

If you’re buying, what kind of company do you prefer most and why?

View Poll

•AI/ML Innovations closed a $950,000 private placement in late March 2026 — with insiders absorbing 58% of the raise, signaling strong internal conviction as the company accelerates its push toward commercialization.

•NeuralCloud's MaxYield™ platform is now embedded in a European cloud-based cardiac monitoring network, giving the company commercial distribution reach without the cost or complexity of building a direct European sales operation.

•A research services agreement with the Baker Heart and Diabetes Institute puts MaxYield™ at the center of a peer-reviewed cardiovascular study — the kind of institutional validation that opens doors with hospital procurement teams and clinical partners.

•Unlike consumer cardiac apps that classify rhythm, MaxYield™ annotates ECG waveforms beat-by-beat — identifying P waves, QRS complexes, and T waves across any device and any species, a technical depth its competitors have not matched.

•With pilots active at SickKids Hospital, the Toronto Heart Centre, and now a European monitoring platform, AIML is no longer a concept-stage company — it is in clinical environments, converting relationships into potential recurring revenue.

This article has been prepared on behalf of AIML Innovations Inc. and is for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities.

Three announcements in the final two weeks of March 2026 reveal a company with a specific and increasingly concrete strategy: embed its ECG signal-processing infrastructure into research institutions, clinical platforms, and distribution networks — and fund the runway to get there. For AI/ML Innovations Inc. (CSE:AIML / OTCQB:AIMLF), the final days of March 2026 were among the most operationally dense in the company's history. Within a span of six days, the Toronto-based AI health company announced a research partnership with one of the world's most respected cardiovascular institutes, closed a $950,000 private placement, and revealed that its Neural Cloud subsidiary had signed a reseller agreement with a European digital cardiac monitoring platform. Taken individually, each announcement reflects incremental progress. Taken together, they sketch the outline of a deliberate commercialization architecture that has been years in the making.

The Technology Underneath Everything

To understand what AIML is building toward, it helps to understand what sits at the center of every deal the company announces: MaxYield™, its proprietary ECG signal-processing engine. Unlike consumer-facing cardiac apps or rhythm classifiers embedded in wearables, MaxYield™ performs beat-by-beat annotation of full ECG waveforms — isolating and labeling P waves, QRS complexes, and T waves while extracting interval data at the beat level. The distinction matters clinically. Most incumbent platforms, including those embedded in consumer wearables from major technology companies, perform rhythm classification only — they identify what a cardiac rhythm is doing. MaxYield™ is designed to identify why the heart is producing a given signal, a fundamentally different level of signal interpretation.

The platform has been validated across human, equine, and canine cardiac morphologies — a technical proof of architectural generalization that the company argues single-species competitors cannot match. It processes signals from any device, from single-lead consumer patches to 12-lead clinical systems, and operates as a cloud-native infrastructure layer designed to integrate into existing clinical and research workflows rather than replace them. The company received a U.S. patent grant (U.S. Patent No. 12,465,266) in November 2025 covering the core ECG signal-processing architecture, with a suite of provisional filings extending protection across neural-network design, cloud-native workflows, and adaptive clinical reporting systems. That IP was developed with Wolf Greenfield & Sacks, a leading life sciences patent firm.

Built on top of MaxYield™ is a layered product stack: CardioYield™, an AI-enabled Holter report automation platform currently advancing through FDA 510(k) review; Insight360™, a wellness and performance analytics platform that is already in-market and generating revenue as of Q1 2026; and a TrueWave.Kit SDK for OEM licensing directly to device manufacturers. A pre-trained Model API — essentially a cardiac AI equivalent of what OpenAI's API provides in the language model space — is targeted for Q1 2027 beta launch.

Baker Heart: Validation at the Research Layer

On March 18th, 2026, NeuralCloud entered into a research services agreement with Dr. Kegan Moneghetti of the Baker Heart and Diabetes Institute to provide AI-powered ECG signal processing in support of an ongoing cardiovascular research study. Under the agreement, NeuralCloud will apply its MaxYield™ platform to existing ECG recordings supplied by the research team, supporting a study evaluating heart rate variability in healthy control subjects compared to individuals experiencing post-exertional malaise — with the goal of identifying measurable physiological differences using high-resolution ECG analytics.

Post-exertional malaise is a defining symptom of ME/CFS and Long COVID, conditions that have attracted significant research funding and clinical attention globally. NeuralCloud will convert PDF ECG traces to European Data Format and run AI-based signal processing, yielding labeled waveform components, beat-level data, and interval measurements suitable for HRV research workflows, with study findings expected to be published within the coming year.

The strategic value of this agreement is not the near-term revenue — the services are non-diagnostic and are not intended for clinical use. The value is the institutional stamp. The Baker Heart and Diabetes Institute is internationally recognized for its leadership in cardiovascular research, prevention, and digital health. WebDisclosure A peer-reviewed publication citing MaxYield™ as the signal processing backbone of a study by this institution would carry far more weight with hospital procurement teams and potential distribution partners than any press release.

"High-quality ECG signal processing is essential for uncovering subtle physiological markers in research settings," said Paul Duffy, Executive Chairman and CEO of AIML. "This engagement demonstrates how NeuralCloud's technology can support leading academic institutions by delivering consistent, reproducible ECG analytics that integrate seamlessly into established research workflows."

Dr. Moneghetti himself lent credibility to the platform directly, noting that NeuralCloud's MaxYield™ provides a structured framework for extracting ECG metrics with potential applications across cardiovascular research. Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AIML, added that the engagement "highlights how MaxYield™ can support rigorous cardiovascular research using real-world ECG data."

It is worth noting that the Baker engagement is not the company's first foray into institutional research settings. The company initiated a pediatric cardiac pilot at SickKids Hospital in November 2025, benchmarked AI-powered Holter reporting at the Toronto Heart Centre in October 2025, and has an ongoing cardiac monitoring deployment at the Heartdent Center in Jamaica. The Baker agreement adds an internationally recognized research institution to a pilot and deployment roster that now spans multiple continents and clinical verticals.

The European Reseller: Commercial Distribution

On March 31st, AIML announced that Neural Cloud had entered into a reseller agreement with a European-based digital health platform specializing in cloud-based ECG and heart rate variability analytics, under which the partner will integrate and resell MaxYield™ as either a standalone capability or as part of a bundled remote cardiac monitoring solution.

The partner's identity was not publicly disclosed. The platform operates as a device-agnostic, cloud-based monitoring environment, enabling cardiologists, general practitioners, and healthcare providers to remotely track patient cardiovascular metrics in real time. Patients connect compatible ECG devices to a mobile application, allowing short ECG recordings to be transmitted securely to the cloud for instant analysis. Mediabistro This deal is structurally significant. Entering European healthcare markets independently would require AIML to navigate complex regulatory frameworks, build or hire local sales infrastructure, and establish clinical relationships from scratch. By embedding MaxYield™ into a platform that already has these relationships and that existing clinical customers, AIML effectively piggybacks on a distribution network that took years to build. The model mirrors what the company has been executing in Latin America, where it signed a distribution agreement with Intelimed in February 2026, and signals that geographic expansion through established platform partners — rather than direct sales — is a deliberate strategic posture.

Erik Suokas, COO of AIML Innovations — who joined in January 2026 following an executive search and brings prior commercial roles at Abbott Medical, St. Jude Medical, and Medtronic — framed the deal in terms of market tailwinds: "This collaboration demonstrates the growing demand for high-quality ECG signal processing within the rapidly expanding field of remote cardiac monitoring. By integrating MaxYield into innovative digital health platforms, we can help clinicians access cleaner signals and more reliable insights, ultimately supporting better patient outcomes."

Suokas's appointment itself is worth noting in this context. His prior track record includes driving approximately 275% revenue growth at Sun Nuclear through a restructured go-to-market strategy and leading 12+ acquisitions in a private equity-backed environment. His hiring was widely interpreted as a signal that AIML was transitioning from a technology development phase to one focused on commercial execution.

The Private Placement: Capital Structure and Insider Signal

On March 27th, AIML closed the first tranche of a non-brokered private placement, issuing convertible debentures in the aggregate principal amount of $950,000. The debentures bear interest at 10% per annum, mature on March 27, 2029, and are convertible into units at $0.05 per unit, with each unit comprising one common share and one warrant exercisable at $0.15 for a period of 36 months.

Insiders of the company participated directly, purchasing $550,000 of the $950,000 raised. Stock Titan That figure — 58% of the total raise — is the most materially important detail in the announcement. When the majority of a capital raise is absorbed by the people with the most visibility into actual operations, product status, and pipeline quality, it is a meaningful signal about internal conviction. The debenture structure, which allows interest to convert to equity under the same terms, also reduces cash repayment pressure during the commercialization runway.

The financial context behind this raise is not without weight. The company's most recent quarterly filings reported approximately C$429,000 in cash as of January 31, 2026, against a monthly operating burn rate of roughly C$400,000. The $950,000 raise extends that runway materially, but the company has explicitly disclosed in its public filings that it will require additional financing to continue operations. Shareholders' equity stood at approximately C$215,000 as of the same date, reflecting the accumulated losses typical of an early-stage company investing heavily ahead of revenue scale. Revenue for the nine months ended January 31, 2026, totaled C$83,058 — meaningful as early validation of platform usage, but not yet at a scale that covers operating costs.

This financial profile is consistent with early-stage AI healthcare companies at a similar inflection point, and the capital being deployed has tangibly funded real assets: a granted U.S. patent, more than 10 active clinical pilots, a 55-person team across clinical, technical, and commercial functions, and parallel regulatory submissions across three jurisdictions.

The Infrastructure Thesis

The company's strategic positioning is best understood not as a diagnostics company competing with iRhythm or Philips Cardiologs at the clinical output layer, but as an infrastructure provider operating upstream of those platforms. NeuralCloud's longer-term roadmap includes ECG annotation services (currently active and generating revenue), AI training infrastructure targeting ECG developers and hospital IT, and the planned Model API — designed to supply pre-trained ECG neural networks to the 60+ Holter manufacturers, wearable makers, and hospital IT systems that need clean, structured signal data to power their own downstream analytics.

The analogy the company draws is to cloud infrastructure — a layer that powers diagnostic tools without competing against them. Whether that positioning proves defensible at scale depends almost entirely on execution milestones over the next 12 months: pilot-to-contract conversions, CardioYield™'s FDA 510(k) outcome, the trajectory of the European and Latin American distribution agreements, and whether the Baker Heart study produces peer-reviewed findings that move the credibility needle with institutional buyers.

What the announcements of late March 2026 confirm is that AIML is no longer solely in the pilot-and-validate phase. It has academic credibility in progress, commercial distribution channels opening on two continents, fresh capital with meaningful insider participation, and a product stack that its management team — now including executives with direct cardiology commercial networks — is actively bringing to market. The distance between where the company is today and where the commercialization thesis requires it to be remains real, but the architecture being assembled is coherent, and the pieces placed in the final weeks of March were among the most consequential the company has announced.

AI/ML Innovations Inc. trades on the Canadian Securities Exchange under the symbol AIML, on the OTCQB under AIMLF, and on the Frankfurt Stock Exchange under 42FB. This article is for informational purposes only and does not constitute investment advice. Readers are encouraged to conduct their own due diligence. This article has been prepared on behalf of AIML Innovations Inc. and is for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell securities.

Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.

The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements are expected to support production of products requiring a Drug Identification Number (DIN), a key authorization for prescription and over-the-counter drug sales in regulated markets.

Strategic Move Into Pharmaceutical Manufacturing and Global Drug Markets

The Burlington facility upgrades mark a significant step in Rapid Dose Therapeutics' evolution from a drug delivery innovation company into a pharmaceutical manufacturing and commercialization platform. The initiative is designed to expand the Company's capabilities across oral thin film drug delivery, pharmaceutical production, and global distribution channels, supporting its proprietary QuickStrip™ fast-dissolving oral thin film technology.

QuickStrip™ is engineered to deliver pharmaceuticals, nutraceuticals, cannabinoids, vaccines and nicotine products through rapid absorption via the oral mucosa, offering advantages in bioavailability, onset time, and patient compliance compared to traditional capsules, tablets, injections and inhalation-based delivery systems.

GMP and EU GMP Alignment Supports International Expansion

In parallel, Rapid Dose is upgrading its existing cannabis production clean rooms to align with Good Manufacturing Practice (GMP) and European Union GMP (EU GMP) standards, reinforcing its readiness to participate in the rapidly expanding global medical cannabis and pharmaceutical export markets.

These upgrades are expected to enable:

• Entry into regulated international pharmaceutical markets
• Expansion of medical cannabis exports
• Increased participation in high-growth non-smoking cannabis formats
• Enhanced attractiveness for strategic partnerships and licensing agreements

The Burlington facility is being developed into a dual-purpose centralized manufacturing hub, capable of supporting both pharmaceutical-grade production and cannabis-based product manufacturing, creating operational efficiencies and long-term scalability.

As of the date of this release. no approvals have been obtained and timelines and outcomes are uncertain.

Positioned for Market Opportunities

The expansion aligns with major global market trends, including:

• The global pharmaceutical market, projected to reach approximately $1.7 trillion by 2030
• Canada's top 10 global pharmaceutical market position
• The global medical cannabis market, projected to reach approximately $65.9 billion by 2030

These markets are being driven by rising demand for innovative drug delivery systems, patient-friendly dosing formats, and compliant manufacturing infrastructure.

Building a Scalable Platform for Long-Term Growth

"This upgrade represents a pivotal step in expanding the strategic value of our Burlington facility," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "By aligning our operations with internationally recognized pharmaceutical standards, we are strengthening our ability to pursue high-growth commercial opportunities while scaling the global reach of our QuickStrip™ platform."

Upon completion, the upgraded facility is expected to deliver:

• Expanded pharmaceutical manufacturing capabilities
• Enhanced regulatory readiness (DEL, DIN pathways)
• Improved operational efficiency and scalability
• Stronger positioning for global partnerships and licensing deals

Sponsored publication on behalf of the issuer

MIAMI, FL / ACCESS Newswire / April 7, 2026 / Sekur Private Data, Inc., a leading Swiss-hosted cybersecurity, private communications, and defense communications company serving enterprise, government, and defense clients, and wholly owned subsidiary of Sekur Private Data (OTCQB:SWISF)(CSE:SKUR)(FRA:GDT0) ("Sekur" or the "Company"), is pleased to announce the appointments of the first two of several Strategic Advisory Board members.

The Board is expected to grow to other members in the coming weeks and months, to complement the various sectors Sekur is planning to offer its secure communications solutions and capabilities. The Strategic Advisory Board will first focus on Government and Federal Agencies, Law Enforcement, Intelligence Community, Defense and Special Operations sectors, reflecting the need for new capabilities to offer communications for Controlled Unclassified Information in various government sectors.

The Company is pleased to announce the following people as members of the Strategic Advisory Board.

Philip A. Oakley - Clearance Level TS/SCI

Philip Oakley is a highly decorated intelligence professional and entrepreneur, holding dual master's degrees in Strategic Intelligence and National Security from the Joint Military Intelligence College and Naval War College respectively, alongside further graduate qualifications in Education Administration. He is a Certified Intelligence Community Officer, Certified Imagery Analyst, and Certified Counterintelligence Agent - credentials that underpin a career spanning elite military intelligence, academia, and private enterprise.

His military career placed him at the highest levels of national security. Based at the Pentagon, Philip prepared and delivered intelligence briefings to the President, Vice President, Secretary of Defense, and Joint Chiefs of Staff, producing over 200 threat assessments to senior leadership. He was notably hand-picked by the Joint Staff J2 to attend the Naval War College - a rare distinction for an Army officer - where he authored a seminal paper recommending the establishment of a Homeland Defense Agency, a concept realized shortly after in the creation of the Department of Homeland Security. During a critical North Korea standoff, he developed an intelligence exchange program that increased production by over 200%, briefing General Officers and the Undersecretary of Defense directly.

Philip was assigned to duty stations including but not limited to the National Ground Intelligence Center (NGIC), Defense Intelligence Agency (DIA) Bolling Air Force Base, US Forces Korea, and the J2 Pentagon. Among his assignments, he was leading an element that prepared the Daily Intelligence Briefings for the Secretary of Defense and Chairman of the Joint Chiefs of Staff and provided briefings to the President of the United States, is also a certified Intelligence Community Officer (ICO). Philip has numerous military awards including Multiple Army Accommodation Medals, Good Conduct Medals, Meritorious Service Medals, and several Defense Meritorious Service Medals.

In academia, Philip served as both Adjunct and Full-Time Professor of Strategic Intelligence at the Joint Military Intelligence College, developing curriculum for over thirty courses and mentoring dozens of graduate thesis committees. He also was personally chosen by the Commanding General of the US Army Intelligence School to shape requirements for Army-wide strategic intelligence officers.

As founder and CEO of i3 Integrative Creative Solutions, Philip has translated this extraordinary background into a thriving Service-Disabled Veteran Owned Business, building sales teams that have exceeded $1.6 billion over 15 years, delivering cutting-edge technology solutions - including Palantir, IBM, and Pixia - to federal, state, and intelligence community clients.

Philip Oakley stated, "I was honored to be asked to be part of the Sekur Strategic Advisory Board. Over the last 16 years I've been part of several technology companies' sales and success in federal sales spaces with over US$1.6 billion in sales within my group of companies. Besides the technical differentiators that will greatly impact the controlled but unclassified information ("CUI") environment, Sekur has assembled an amazing team of federal experienced individuals, joining in the coming weeks. The soon-to-be announced names greatly enhance the credibility of this amazing technology. Simply put, the investment in the federal team speaks volumes about the direction this innovative company is headed in."

Kenneth D. Rogers (Ken Rogers)

Ken Rogers is a seasoned senior government and technology executive with a rare blend of experience across five U.S. federal agencies, multinationals, startups, and global NGOs. He retired in 2024 from the U.S. State Department and was awarded the prestigious Director General's Cup during the Foreign Affairs Day Celebration in 2025. This award recognizes individuals from the contemporary generation of career civil and foreign service employees who have demonstrated exceptional service and commitment and was only issued to two members in 2024.

With over 15 years at the U.S. Department of State, where he rose to serve as Deputy CIO for Business Management and Planning, IT Comptroller, and Chief Digital Strategist. In these roles he held direct budgetary responsibility of approximately US$1.3 billion while overseeing a global $3.8 billion IT portfolio spanning 85,000 personnel across more than 300 locations worldwide. He led IT strategic workforce planning, acquisitions, enterprise architecture, and portfolio management, while serving as the primary liaison between the State Department, the White House, and the Office of Management and Budget. Key achievements included implementing FITARA, developing the Department's cloud strategy, and re-engineering IT acquisition across the organisation.

Prior to his State Department tenure, Ken served as Chief Information Officer at the U.S. Department of Homeland Security's Science & Technology Directorate, where he oversaw a $75 million IT portfolio supporting a $1.3 billion homeland security R&D organization. His remit encompassed IT investments, infrastructure, interoperability across DHS labs, DOE National Labs, and Academic Centers of Excellence, ensuring full regulatory compliance across a complex and sensitive technology environment.

Alongside his government roles, Ken served as Faculty Chair for Cyberspace Strategies at the National Defense University's College of Information and Cyberspace, educating military, civilian, and international leaders on securing and managing information technology at the enterprise level. He has also advised foreign governments on national IT governance strategies, reflecting a breadth of influence that extends well beyond domestic policy.

Ken was immediately attracted to Sekur‘s solutions set because of its ability to provide more secure communications between the Department of States and its diplomatic counterparts in over 200 countries using voice and video call, messaging and email capabilities. These tools also provide other civilian agencies with similar needed capabilities including the Department of Homeland Security's engagement with first responders' nationwide.

Ken Rogers stated, "I am honored to be part of the Sekur leadership team and look forward to bringing this groundbreaking secure messaging and communications platform to industry and government. Sekur delivers a world-class end-to-end encrypted solution designed to ensure that sensitive documents and information are shared only with their intended audiences-privately, securely, and with confidence."

Alain Ghiai, CEO of Sekur, commented: "We are honored to welcome Philip Oakley and Kenneth Rogers to our Strategic Advisory Board. Their expertise will be instrumental in introducing Sekur's secure communications capabilities across the Defense, Intelligence Community, Law Enforcement, and Federal spaces - particularly in filling the void that exists in the Controlled Unclassified Information (CUI) space. We look forward to expanding the board and working toward becoming an essential provider of secure communications to all who serve the U.S. Government, domestically and globally."

Core Defense & Government Communications Solutions:
Sekur delivers mission-critical secure communications operable within and outside the Sekur network, bypassing traditional telecom infrastructure and eliminating exposure to interception, phone record hacking, and network surveillance. No Sekur solution data mines or location tracks users. All solutions are built on proprietary architecture with zero reliance on Big Tech infrastructure or open-source coding - engineered for defense, intelligence, and federal agency operational environments. Government solutions are provided with an on-premises infrastructure for data sovereignty.

SekurMail: A defense-grade encrypted email solution built for personnel operating at the highest levels of government and military command. With zero Big Tech reliance, no tracking, and proprietary encryption, it ensures mission-sensitive communications remain strictly confidential for both sender and recipient. Capabilities include SekurSend/SekurReply for secure transmission to non-Sekur users without compromising identities or content, full email delivery control, automatic data export, file transfer, custom domain support, and active countermeasures against phishing and Business Email Compromise (BEC) attacks.

SekurMessenger: A hardened field-ready secure messaging platform featuring end-to-end encryption, self-destructing messages, encrypted file transfers, encrypted voice recordings, and compliance archiving. Supports cross-network secure communications capabilities with non-Sekur users via Chat-by-Invite. Each operator is assigned a unique Sekur ID for contact vetting, with no phone number required - preserving anonymity and operational security.

SekurVPN: A defense-grade VPN leveraging military-standard encryption and proprietary HeliX technology, with capabilities providing secure internet access and identity protection and obfuscation for personnel operating in sensitive, forward, or hostile environments, with zero data logging.

SekurRelay: A command-level enterprise email solution that splits an organisation's domain, enabling secure communications at the executive or command level without requiring full organizational migration - eliminating a critical barrier to large-scale defense and government deployment.

SekurVoice: A fully encrypted Voice and Video communications platform built on proprietary HeliX data transfer technology and capability, engineered to defeat telecom network tracing and resist Pegasus-style malware intrusion. Call-by-Invite capability via SMS or sekur/send email ensures controlled operator access, with each user assigned a Sekur ID for operational vetting and no phone number required - purpose-built for Controlled Unclassified Information and covert and classified-adjacent communications.

About Sekur Private Data
Sekur Private Data is a Swiss-hosted cybersecurity, defense communications, and privacy solutions provider, offering a secure suite of tools to protect governments, defense and federal agencies, businesses, and individuals from unauthorized access and cyber threats. With capabilities such as SekurMail, SekurMessenger, and SekurVPN, Sekur provides a reliable and secure means of digital communication and data storage for Controlled Unclassified Information (CIU), classified-adjacent and civilian communications use, grounded in Swiss privacy standards with on-premises infrastructure for government agencies, allowing for data sovereignty. Sekur sells its solutions through its website www.sekur.com, approved distributors and telecommunications companies globally, and through the U.S. General Services Administration (GSA) Multiple Award Schedule (MAS), Contract No. 47QTCA18D0089 serving governments, defense institutions, federal agencies, businesses, and consumers worldwide. Sekur's main sales operations are in Miami, USA.